Fig. 1. SF1126 inhibits human CRC cell survival, proliferation, and cell cycle progression. HT-29 cells (A-D), primary human colon cancer cells ("pri-Can-1/2", E and F), or primary human colon epithelial cells ("pri-Epi-1/-2", E and F) were left untreated ("C", same in all Fig.s) or were treated with applied concentrations(0.2-10 μM) of SF1126. Cells were further cultured for the indicated times and cell survival (A, B, and E), cell proliferation (C and F), and cell cycle progression (D) were tested by the appropriate assays. Data are presented as the mean ± standard deviation (in all Fig.s). Five replicate wells/dishes were set up for each treatment (in all Fig.s). *p< 0.05 vs. the "C" group. The experiments were repeated three times, with similar results obtained.